Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up – Time to Buy?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) shares gapped up prior to trading on Monday. The stock had previously closed at $4.55, but opened at $4.78. Gyre Therapeutics shares last traded at $5.0050, with a volume of 74,317 shares changing hands.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Zacks Research upgraded Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 6th. Wall Street Zen downgraded Gyre Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Gyre Therapeutics in a report on Friday, August 7th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Reduce”.

Gyre Therapeutics Stock Up 3.4%

The stock has a market cap of $524.65 million, a price-to-earnings ratio of -22.40 and a beta of 1.89. The company’s 50-day moving average is $6.73 and its 200-day moving average is $6.99.

Gyre Therapeutics (NASDAQ:GYRE) last posted its earnings results on Friday, August 7th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Gyre Therapeutics had a negative return on equity of 6.57% and a negative net margin of 15.47%. The company had revenue of $29.11 million for the quarter, compared to the consensus estimate of $26.49 million. On average, research analysts forecast that Gyre Therapeutics, Inc. will post -0.61 earnings per share for the current year.

Institutional Trading of Gyre Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE acquired a new position in shares of Gyre Therapeutics in the 2nd quarter worth approximately $83,000. Deutsche Bank AG bought a new stake in Gyre Therapeutics during the 2nd quarter worth approximately $118,000. Dimensional Fund Advisors LP increased its holdings in Gyre Therapeutics by 131.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company’s stock valued at $176,000 after purchasing an additional 14,365 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Gyre Therapeutics by 4.7% during the 1st quarter. Bank of New York Mellon Corp now owns 43,144 shares of the company’s stock valued at $301,000 after purchasing an additional 1,941 shares in the last quarter. Finally, SBI Securities Co. Ltd. raised its position in Gyre Therapeutics by 1.8% in the 3rd quarter. SBI Securities Co. Ltd. now owns 169,717 shares of the company’s stock valued at $1,244,000 after purchasing an additional 2,967 shares during the last quarter. 23.99% of the stock is owned by institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a biopharmaceutical company focused on developing therapies for fibrotic diseases, including pulmonary and liver fibrosis. The company’s lead development program is F351, also known as hydronidone, an investigational small-molecule therapy designed to inhibit the progression of fibrosis.

F351 is being evaluated in clinical programs for idiopathic pulmonary fibrosis and liver fibrosis associated with chronic liver disease, including nonalcoholic steatohepatitis-related fibrosis.